MIND studies neurodegenerative disorders, most importantly Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Huntington's disease, and Parkinson's disease.
Amyotrophic Lateral Sclerosis
ALS, or Lou Gehrig’s disease, is a life-threatening neurodegenerative disease with an estimated prevalence in the United States of 30,000 and an average life expectancy from diagnosis of only two to five years.Introduction to ALS Research Healey Center for ALS
Alzheimer’s disease (AD) is a neurodegenerative disease affecting approximately 10% of individuals over the age of 65 and nearly one-third of those over 85, making it the most common cause of dementia. Over 300 billion dollars are spent on Alzheimer's care each year.Introduction to Alzheimer's Research Memory Disorders Division
Huntington’s disease (HD) is one of the more common neurodegenerative diseases with an estimated 250,000 people in the United States either diagnosed with, or at risk for, the disease. The typical age of HD onset is between the ages of 30 and 50, with very rare juvenile onset as young as two years old and the average lifespan once diagnosed with HD is 10-20 years.Introduction to HD Research Huntington's Center of Excellence
The second most frequently diagnosed neurodegenerative disease after Alzheimer’s disease is Parkinson’s disease (PD). PD onset is usually after the age of 60 and affects about five million people globally. This number is expected to keep rising as the population ages.Introduction to Parkinson's Research Parkinson's & Movement Disorders Clinic
HEALEY ALS Platform Trial
Find out about the innovative new HEALEY ALS Platform Trial, which is accelerating efforts to bring new ALS treatments to patients.
Neurology Research at Mass General
Explore current research projects in the Department of Neurology or search our open clinical trials and medical research studies.
Your contributions help drive discovery and propel findings from the laboratory bench into the clinic.